Is Broach Lifecare overvalued or undervalued?

As of 6 November 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 20.23, an EV to EBITDA of 11.78, and a ROCE of 6.90%.
In comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than that of Apollo Hospitals, which stands at 71.27, highlighting a substantial valuation gap. Additionally, while Broach Lifecare's PEG Ratio is at 0.00, indicating no growth expectations, other peers like Max Healthcare and Fortis Health are considered very expensive with PEG Ratios of 6.38 and 1.88, respectively. Despite a recent stock return of 3.75% over the past week, Broach Lifecare has underperformed the Sensex over the longer term, with a year-to-date decline of 16.67% compared to the Sensex's gain of 6.62%.